Abstract
High-dose (100 mg/m2 body surface) cisplatinum (CPL) for treatment of osteogenic sarcoma causes a considerable degree of nephrotoxicity. We studied 18 patients receiving high-dose CPL 37 times. In 17 treatment episodes amiloride, a diuretic agent, was given (dosage about 0.15 mg/kg body weight). Renal function was monitored by endogenous creatinine clearance (CC), serum β2-microglobulin (β2-M), urinary β2-M and alanin-aminopeptidase (AAP) urinary excretion. In response to CPL administration urinary β2-M and AAP rose tremendously with a peak level about 25 times and a 24 hours excretion about ten-fold higher than before CPL treatment. Serum β2-M and CC were less alterated. After additional use of amiloride urinary β2-M showed a peak level below 30 per cent and a 24 hours excretion below 45 per cent compared to the treatment episodes without amiloride. The AAP excretion did not change significantly. The different effect of amiloride on β2-M and AAP may give a hint to its way of action, since these two substances indicate tubular damage of different localization.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amon, O., Winkler, K. & Bläker, F. 164 REDUCED NEPHROTOXICITY OF CISPLATINUM BY USE OF AMILORIDE. Pediatr Res 20, 1061 (1986). https://doi.org/10.1203/00006450-198610000-00219
Issue Date:
DOI: https://doi.org/10.1203/00006450-198610000-00219